IL313292A - Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 - Google Patents
Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2Info
- Publication number
- IL313292A IL313292A IL313292A IL31329224A IL313292A IL 313292 A IL313292 A IL 313292A IL 313292 A IL313292 A IL 313292A IL 31329224 A IL31329224 A IL 31329224A IL 313292 A IL313292 A IL 313292A
- Authority
- IL
- Israel
- Prior art keywords
- ethan
- fluoropyridin
- hemi
- butylamino
- hyperglycemia
- Prior art date
Links
- SASMSPQPEDQJII-JTQLQIEISA-N C(C)(C)(C)NC[C@H](O)C=1C=NC=C(C=1)F Chemical compound C(C)(C)(C)NC[C@H](O)C=1C=NC=C(C=1)F SASMSPQPEDQJII-JTQLQIEISA-N 0.000 title 1
- 201000001421 hyperglycemia Diseases 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2117828.0A GB2613616A (en) | 2021-12-09 | 2021-12-09 | New formulations |
| PCT/EP2022/085133 WO2023105035A1 (en) | 2021-12-09 | 2022-12-09 | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL313292A true IL313292A (en) | 2024-08-01 |
Family
ID=80079964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313292A IL313292A (en) | 2021-12-09 | 2022-12-09 | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250042856A1 (enExample) |
| EP (1) | EP4444699A1 (enExample) |
| JP (1) | JP2024544698A (enExample) |
| KR (1) | KR20240116482A (enExample) |
| CN (1) | CN118525004A (enExample) |
| AU (1) | AU2022405700A1 (enExample) |
| CA (1) | CA3241501A1 (enExample) |
| GB (1) | GB2613616A (enExample) |
| IL (1) | IL313292A (enExample) |
| MX (1) | MX2024006960A (enExample) |
| WO (1) | WO2023105035A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202303229D0 (en) * | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| BR112021018481A2 (pt) * | 2019-03-27 | 2021-11-23 | Curasen Therapeutics Inc | Agonista adrenérgico beta e métodos para usar o mesmo |
-
2021
- 2021-12-09 GB GB2117828.0A patent/GB2613616A/en active Pending
-
2022
- 2022-12-09 US US18/717,134 patent/US20250042856A1/en active Pending
- 2022-12-09 MX MX2024006960A patent/MX2024006960A/es unknown
- 2022-12-09 WO PCT/EP2022/085133 patent/WO2023105035A1/en not_active Ceased
- 2022-12-09 EP EP22835607.7A patent/EP4444699A1/en active Pending
- 2022-12-09 IL IL313292A patent/IL313292A/en unknown
- 2022-12-09 CN CN202280081693.4A patent/CN118525004A/zh active Pending
- 2022-12-09 AU AU2022405700A patent/AU2022405700A1/en active Pending
- 2022-12-09 KR KR1020247020161A patent/KR20240116482A/ko active Pending
- 2022-12-09 JP JP2024534196A patent/JP2024544698A/ja active Pending
- 2022-12-09 CA CA3241501A patent/CA3241501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118525004A (zh) | 2024-08-20 |
| GB202117828D0 (en) | 2022-01-26 |
| MX2024006960A (es) | 2024-06-24 |
| AU2022405700A1 (en) | 2024-06-20 |
| GB2613616A (en) | 2023-06-14 |
| CA3241501A1 (en) | 2023-06-15 |
| EP4444699A1 (en) | 2024-10-16 |
| WO2023105035A1 (en) | 2023-06-15 |
| JP2024544698A (ja) | 2024-12-03 |
| KR20240116482A (ko) | 2024-07-29 |
| US20250042856A1 (en) | 2025-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE059624T2 (hu) | N-(fenil)-2-(fenil)pirimidin-4-karboxamid származékok és rokon vegyületek HPK1-inhibitorokként rák kezelésére | |
| JP1704655S (ja) | 医療用注入器 | |
| IL327282A (en) | New treatments for pain | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP1705349S (ja) | 医療用注入器 | |
| JP2018501226A5 (enExample) | ||
| PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| CY1117962T1 (el) | Υδροχλωρικο αλας 4-[2-[[5-μεθυλο-1-(2- ναφθαλενυλο)-1η- πυραζολ-3-υλ]οξυ]αιθυλο] μορφολινης | |
| JOP20240235A1 (ar) | مركبات أريل غير متجانسة لمعالجة الألم | |
| PL4289824T3 (pl) | Związek uracylowy zawierający fragment karboksylanowy i sposób jego przygotowania, kompozycja chwastobójcza i zastosowanie | |
| EP4495117A4 (en) | HETEROCYCLIC COMPOUND CONTAINING NITROGEN AND ITS USE | |
| MX390332B (es) | Una composición farmacéutica que comprende febuxostat e inosina para usarse en el tratamiento de enfermedades en donde existe una deficiencia de atp intracelular. | |
| EP4333748C0 (de) | Medizinisches implantat zur osteosynthese | |
| JP1767705S (ja) | 医療用注入器 | |
| NZ735783A (en) | Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof. | |
| HK40117732A (en) | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 | |
| MD4844B1 (ro) | Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi | |
| IL272443A (en) | Glycyrrhetinic acid derivatives for treating hyperkalemia | |
| EP4393510A4 (en) | OPHTHALMOLOGICAL COMPOSITION | |
| IL284950A (en) | Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder | |
| KR102319110B9 (ko) | 세포성 바이오 의약품의 장기 보존을 위한 동결보존액 조성물 | |
| EP4135643C0 (en) | PATIENT POSITIONING | |
| EP4129294A4 (en) | MEDICATION FOR THE TREATMENT OF PAIN |